Somatostatin Receptor (SSTR) Scintigraphy in Patients with Osteosarcoma

Stefano Ferrari, Maurizio Dondi, Stefano Fanti, Stefania Zoboli, Stefano Giacomini, Mario Mercuri, Gaetano Bacci

Research output: Contribution to journalArticle

Abstract

To investigate somatostatin receptors (SSTRs) in primary or metastatic high-grade osteosarcoma, 18 patients (12 without metastases, 4 with synchronous lung, and 2 with metachronous bone metastases) underwent SSTR scintigraphy. After intravenous (i.v.) injection of 200-250 MPq of 111In-pentreotide, images were recorded at 4 and 24 hours. All patients underwent 99mTc-methylene diphosphonate (MDP) bone scan (BS). Scans were interpreted both with qualitative evaluation and with semiquantitative image processing, by means of tumor-to-background ratio modification over time. Primary tumor: SSTR scintigraphy was positive in 12 (75%) patients: 10 (83%) of the 12 nonmetastatic patients, and 2 (50%) of those with synchronous metastases. Metastases: SSTR scintigraphy was positive only in one (17%) of the six patients with metastatic disease. No relation was found between SSTR scintigraphy results and gender, histologic subtype, site, and size of the tumor. After primary chemotherapy, 15 patients underwent surgery of primary tumor; a good histologic response was found in 7 (64%) of the 11 patients with positive SSTR scintigraphy versus 1 (25%) of the 4 patients with negative SSTR scintigraphy. High-grade osteosarcoma exhibits somatostatin receptors, usually detectable in the primary tumor, but not in the metastatic lesions. The different expression of somatostatin receptors observed in primary and metastatic lesions, and in patients with tumors having different chemosensitivity, could indicate a possible relation between somatostatin receptors and biological behavior of the tumor.

Original languageEnglish
Pages (from-to)847-851
Number of pages5
JournalCancer Biotherapy and Radiopharmaceuticals
Volume18
Issue number5
Publication statusPublished - 2003

Fingerprint

Somatostatin Receptors
Osteosarcoma
Radionuclide Imaging
Neoplasms
Neoplasm Metastasis
Technetium Tc 99m Medronate
Bone and Bones
Intravenous Injections
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Ferrari, S., Dondi, M., Fanti, S., Zoboli, S., Giacomini, S., Mercuri, M., & Bacci, G. (2003). Somatostatin Receptor (SSTR) Scintigraphy in Patients with Osteosarcoma. Cancer Biotherapy and Radiopharmaceuticals, 18(5), 847-851.

Somatostatin Receptor (SSTR) Scintigraphy in Patients with Osteosarcoma. / Ferrari, Stefano; Dondi, Maurizio; Fanti, Stefano; Zoboli, Stefania; Giacomini, Stefano; Mercuri, Mario; Bacci, Gaetano.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 18, No. 5, 2003, p. 847-851.

Research output: Contribution to journalArticle

Ferrari, S, Dondi, M, Fanti, S, Zoboli, S, Giacomini, S, Mercuri, M & Bacci, G 2003, 'Somatostatin Receptor (SSTR) Scintigraphy in Patients with Osteosarcoma', Cancer Biotherapy and Radiopharmaceuticals, vol. 18, no. 5, pp. 847-851.
Ferrari S, Dondi M, Fanti S, Zoboli S, Giacomini S, Mercuri M et al. Somatostatin Receptor (SSTR) Scintigraphy in Patients with Osteosarcoma. Cancer Biotherapy and Radiopharmaceuticals. 2003;18(5):847-851.
Ferrari, Stefano ; Dondi, Maurizio ; Fanti, Stefano ; Zoboli, Stefania ; Giacomini, Stefano ; Mercuri, Mario ; Bacci, Gaetano. / Somatostatin Receptor (SSTR) Scintigraphy in Patients with Osteosarcoma. In: Cancer Biotherapy and Radiopharmaceuticals. 2003 ; Vol. 18, No. 5. pp. 847-851.
@article{974ca2375e024906a7f9f66753cb03cb,
title = "Somatostatin Receptor (SSTR) Scintigraphy in Patients with Osteosarcoma",
abstract = "To investigate somatostatin receptors (SSTRs) in primary or metastatic high-grade osteosarcoma, 18 patients (12 without metastases, 4 with synchronous lung, and 2 with metachronous bone metastases) underwent SSTR scintigraphy. After intravenous (i.v.) injection of 200-250 MPq of 111In-pentreotide, images were recorded at 4 and 24 hours. All patients underwent 99mTc-methylene diphosphonate (MDP) bone scan (BS). Scans were interpreted both with qualitative evaluation and with semiquantitative image processing, by means of tumor-to-background ratio modification over time. Primary tumor: SSTR scintigraphy was positive in 12 (75{\%}) patients: 10 (83{\%}) of the 12 nonmetastatic patients, and 2 (50{\%}) of those with synchronous metastases. Metastases: SSTR scintigraphy was positive only in one (17{\%}) of the six patients with metastatic disease. No relation was found between SSTR scintigraphy results and gender, histologic subtype, site, and size of the tumor. After primary chemotherapy, 15 patients underwent surgery of primary tumor; a good histologic response was found in 7 (64{\%}) of the 11 patients with positive SSTR scintigraphy versus 1 (25{\%}) of the 4 patients with negative SSTR scintigraphy. High-grade osteosarcoma exhibits somatostatin receptors, usually detectable in the primary tumor, but not in the metastatic lesions. The different expression of somatostatin receptors observed in primary and metastatic lesions, and in patients with tumors having different chemosensitivity, could indicate a possible relation between somatostatin receptors and biological behavior of the tumor.",
author = "Stefano Ferrari and Maurizio Dondi and Stefano Fanti and Stefania Zoboli and Stefano Giacomini and Mario Mercuri and Gaetano Bacci",
year = "2003",
language = "English",
volume = "18",
pages = "847--851",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Somatostatin Receptor (SSTR) Scintigraphy in Patients with Osteosarcoma

AU - Ferrari, Stefano

AU - Dondi, Maurizio

AU - Fanti, Stefano

AU - Zoboli, Stefania

AU - Giacomini, Stefano

AU - Mercuri, Mario

AU - Bacci, Gaetano

PY - 2003

Y1 - 2003

N2 - To investigate somatostatin receptors (SSTRs) in primary or metastatic high-grade osteosarcoma, 18 patients (12 without metastases, 4 with synchronous lung, and 2 with metachronous bone metastases) underwent SSTR scintigraphy. After intravenous (i.v.) injection of 200-250 MPq of 111In-pentreotide, images were recorded at 4 and 24 hours. All patients underwent 99mTc-methylene diphosphonate (MDP) bone scan (BS). Scans were interpreted both with qualitative evaluation and with semiquantitative image processing, by means of tumor-to-background ratio modification over time. Primary tumor: SSTR scintigraphy was positive in 12 (75%) patients: 10 (83%) of the 12 nonmetastatic patients, and 2 (50%) of those with synchronous metastases. Metastases: SSTR scintigraphy was positive only in one (17%) of the six patients with metastatic disease. No relation was found between SSTR scintigraphy results and gender, histologic subtype, site, and size of the tumor. After primary chemotherapy, 15 patients underwent surgery of primary tumor; a good histologic response was found in 7 (64%) of the 11 patients with positive SSTR scintigraphy versus 1 (25%) of the 4 patients with negative SSTR scintigraphy. High-grade osteosarcoma exhibits somatostatin receptors, usually detectable in the primary tumor, but not in the metastatic lesions. The different expression of somatostatin receptors observed in primary and metastatic lesions, and in patients with tumors having different chemosensitivity, could indicate a possible relation between somatostatin receptors and biological behavior of the tumor.

AB - To investigate somatostatin receptors (SSTRs) in primary or metastatic high-grade osteosarcoma, 18 patients (12 without metastases, 4 with synchronous lung, and 2 with metachronous bone metastases) underwent SSTR scintigraphy. After intravenous (i.v.) injection of 200-250 MPq of 111In-pentreotide, images were recorded at 4 and 24 hours. All patients underwent 99mTc-methylene diphosphonate (MDP) bone scan (BS). Scans were interpreted both with qualitative evaluation and with semiquantitative image processing, by means of tumor-to-background ratio modification over time. Primary tumor: SSTR scintigraphy was positive in 12 (75%) patients: 10 (83%) of the 12 nonmetastatic patients, and 2 (50%) of those with synchronous metastases. Metastases: SSTR scintigraphy was positive only in one (17%) of the six patients with metastatic disease. No relation was found between SSTR scintigraphy results and gender, histologic subtype, site, and size of the tumor. After primary chemotherapy, 15 patients underwent surgery of primary tumor; a good histologic response was found in 7 (64%) of the 11 patients with positive SSTR scintigraphy versus 1 (25%) of the 4 patients with negative SSTR scintigraphy. High-grade osteosarcoma exhibits somatostatin receptors, usually detectable in the primary tumor, but not in the metastatic lesions. The different expression of somatostatin receptors observed in primary and metastatic lesions, and in patients with tumors having different chemosensitivity, could indicate a possible relation between somatostatin receptors and biological behavior of the tumor.

UR - http://www.scopus.com/inward/record.url?scp=0242581453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242581453&partnerID=8YFLogxK

M3 - Article

C2 - 14629833

AN - SCOPUS:0242581453

VL - 18

SP - 847

EP - 851

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 5

ER -